121 related articles for article (PubMed ID: 32198958)
1. Complementarity of gluCEST and
Pépin J; de Longprez L; Trovero F; Brouillet E; Valette J; Flament J
NMR Biomed; 2020 Jul; 33(7):e4301. PubMed ID: 32198958
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease.
Pépin J; Francelle L; Carrillo-de Sauvage MA; de Longprez L; Gipchtein P; Cambon K; Valette J; Brouillet E; Flament J
Neuroimage; 2016 Oct; 139():53-64. PubMed ID: 27318215
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal multimodal MRI characterization of a knock-in mouse model of Huntington's disease reveals early gray and white matter alterations.
Pérot JB; Célestine M; Palombo M; Dhenain M; Humbert S; Brouillet E; Flament J
Hum Mol Genet; 2022 Oct; 31(21):3581-3596. PubMed ID: 35147158
[TBL] [Abstract][Full Text] [Related]
4. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy.
Sawiak SJ; Wood NI; Morton AJ
J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
Flament J; Hantraye P; Valette J
Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
[TBL] [Abstract][Full Text] [Related]
6. In vivo GluCEST MRI: Reproducibility, background contribution and source of glutamate changes in the MPTP model of Parkinson's disease.
Bagga P; Pickup S; Crescenzi R; Martinez D; Borthakur A; D'Aquilla K; Singh A; Verma G; Detre JA; Greenberg J; Hariharan H; Reddy R
Sci Rep; 2018 Feb; 8(1):2883. PubMed ID: 29440753
[TBL] [Abstract][Full Text] [Related]
7. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.
Unschuld PG; Edden RA; Carass A; Liu X; Shanahan M; Wang X; Oishi K; Brandt J; Bassett SS; Redgrave GW; Margolis RL; van Zijl PC; Barker PB; Ross CA
Mov Disord; 2012 Jun; 27(7):895-902. PubMed ID: 22649062
[TBL] [Abstract][Full Text] [Related]
8. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.
Petrella LI; Castelhano JM; Ribeiro M; Sereno JV; Gonçalves SI; Laço MN; Hayden MR; Rego AC; Castelo-Branco M
Hum Mol Genet; 2018 Jun; 27(12):2125-2137. PubMed ID: 29668904
[TBL] [Abstract][Full Text] [Related]
9. Neurochemical correlates of caudate atrophy in Huntington's disease.
Padowski JM; Weaver KE; Richards TL; Laurino MY; Samii A; Aylward EH; Conley KE
Mov Disord; 2014 Mar; 29(3):327-35. PubMed ID: 24442623
[TBL] [Abstract][Full Text] [Related]
10. Whole brain mapping of glutamate distribution in adult and old primates at 11.7T.
Garin CM; Nadkarni NA; Pépin J; Flament J; Dhenain M
Neuroimage; 2022 May; 251():118984. PubMed ID: 35149230
[TBL] [Abstract][Full Text] [Related]
11. Neurochemical correlates of synapse density in a Huntington's disease mouse model.
Zarate N; Gundry K; Yu D; Casby J; Eberly LE; Öz G; Gomez-Pastor R
J Neurochem; 2023 Jan; 164(2):226-241. PubMed ID: 36272099
[TBL] [Abstract][Full Text] [Related]
12. Cerebral mapping of glutamate using chemical exchange saturation transfer imaging in a rat model of stress-induced sleep disturbance at 7.0T.
Lee DH; Woo CW; Kwon JI; Chae YJ; Ham SJ; Suh JY; Kim ST; Kim JK; Kim KW; Woo DC; Lee DW
J Magn Reson Imaging; 2019 Dec; 50(6):1866-1872. PubMed ID: 31033089
[TBL] [Abstract][Full Text] [Related]
13. Creatine supplementation lowers brain glutamate levels in Huntington's disease.
Bender A; Auer DP; Merl T; Reilmann R; Saemann P; Yassouridis A; Bender J; Weindl A; Dose M; Gasser T; Klopstock T
J Neurol; 2005 Jan; 252(1):36-41. PubMed ID: 15672208
[TBL] [Abstract][Full Text] [Related]
14. In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy.
Crescenzi R; DeBrosse C; Nanga RP; Reddy S; Haris M; Hariharan H; Iba M; Lee VM; Detre JA; Borthakur A; Reddy R
Neuroimage; 2014 Nov; 101():185-92. PubMed ID: 25003815
[TBL] [Abstract][Full Text] [Related]
15. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.
Behrens PF; Franz P; Woodman B; Lindenberg KS; Landwehrmeyer GB
Brain; 2002 Aug; 125(Pt 8):1908-22. PubMed ID: 12135980
[TBL] [Abstract][Full Text] [Related]
16. Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.
Bagga P; Crescenzi R; Krishnamoorthy G; Verma G; Nanga RP; Reddy D; Greenberg J; Detre JA; Hariharan H; Reddy R
J Neurochem; 2016 Nov; 139(3):432-439. PubMed ID: 27529288
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal metabolite changes in Huntington's disease during disease onset.
van den Bogaard SJ; Dumas EM; Teeuwisse WM; Kan HE; Webb A; van Buchem MA; Roos RA; van der Grond J
J Huntingtons Dis; 2014; 3(4):377-86. PubMed ID: 25575959
[TBL] [Abstract][Full Text] [Related]
18. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
[TBL] [Abstract][Full Text] [Related]
19. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.
Nicniocaill B; Haraldsson B; Hansson O; O'Connor WT; Brundin P
Eur J Neurosci; 2001 Jan; 13(1):206-10. PubMed ID: 11135020
[TBL] [Abstract][Full Text] [Related]
20. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
